TCT 2018 | ReCre8 trial: Zotarolimus y polímero permanente vs Amphilimus libre de polímero

TCT 2018 | ReCre8 Trial: Permanent Polymer and Zotarolimus vs. Polymer-Free Amphilimus

Polymer-free amphilimus-eluting stents are a novel technology combining sirolimus and long-chained fatty acids. This enhances the uptake of antiproliferative agents and may be associated with lower restenosis, particularly among patients with diabetes. The new device includes abluminal reservoirs filled with the drug; in consequence, there is no need for polymer. This work compares this new<a href="https://solaci.org/en/2018/10/08/tct-2018-recre8-trial-permanent-polymer-and-zotarolimus-vs-polymer-free-amphilimus/" title="Read more" >...</a>

Antiaggregation Time after Treating Bifurcations

Defining dual antiplatelet therapy (DAPT) seems a never-ending story. We go from trials showing the safety of shorter schemes thanks to new generation stents to others suggesting up to two years of DAPT. Rather than finding a general scheme, it seems to be about adjusting DAPT on a case by case basis, according to ischemia<a href="https://solaci.org/en/2018/09/06/antiaggregation-time-after-treating-bifurcations/" title="Read more" >...</a>

Mortalidad y volumen de angioplastias de un centro ¿Tienen relación?

The Dangerous Combination of Complex Angioplasty and High Bleeding Risk Seems to Have a Solution

The LEADERS FREE trial demonstrated that a polymer-free Biolimus A9-coated stent (BioFreedom™DCS; Biosensors Europe, Morges, Switzerland) is superior to a conventional stent (bare metal stent, BMS) in patients with high bleeding risk treated with only one month of dual antiplatelet therapy. Now, is this global study outcome applicable in cases of complex lesions with several<a href="https://solaci.org/en/2018/08/21/the-dangerous-combination-of-complex-angioplasty-and-high-bleeding-risk-seems-to-have-a-solution/" title="Read more" >...</a>

See the presentations of the 2018 Guatemala Sessions

SOLACI thanks the 210 attendees ─physicians, nurses, technicians and other professionals. Without them, we would not have achieved such scientific success at these regional sessions. We would also like to extend our appreciation to the Guatemalan Cardiology Association, to the organization, and to the entire Guatemala for the hospitality and generosity they graciously bestowed upon<a href="https://solaci.org/en/2018/07/03/see-the-presentations-of-the-2018-guatemala-sessions/" title="Read more" >...</a>

EuroPCR 2018 | DESSOLV III: polímero bioabsorbible vs durable a 2 años

EuroPCR 2018 | DESSOLV III: Bioabsorbable vs. Durable Polymer at 2 Years

Most drug-eluting stents are coated by a polymer that is used to contain the antiproliferative drug. Once the drug is released, the polymer remains in place and its presence has been associated with inflammation, restenosis, and neoatherosclerosis. The MiStent device features a polymer that becomes bioabsorbable once the drug has been released, which could, theoretically,<a href="https://solaci.org/en/2018/05/31/europcr-2018-dessolv-iii-bioabsorbable-vs-durable-polymer-at-2-years/" title="Read more" >...</a>

ACC 2018 | SMART-DATE: 6 Month DAPT Results Suboptimal in ACS

This study compared 6 vs 12 or more months of dual antiplatelet therapy (DAPT) in patients undergoing acute coronary syndrome (ACS) receiving contemporary DES, and it did not find differences in combined endpoint. However, looking at primary endpoint components separately, there were more infarctions in patients with a short DAPT scheme that we cannot ignore. Prolonging antiaggregation<a href="https://solaci.org/en/2018/04/08/acc-2018-smart-date-6-month-dapt-results-suboptimal-in-acs/" title="Read more" >...</a>

THEMIS: eventos isquémicos y hemorrágicos en difícil equilibrio para el ticagrelor crónico

New Study Shows Ticagrelor + Aspirin Reduce Events Rate

Just when we were starting to understand how long dual antiplatelet therapy should be for our patients, JACC publishes this study where ticagrelor combined with aspirin significantly reduces relative and absolute events rate at long term, especially in patients with multivessel disease. The PEGASUS-TIMI 54 assessed the long-term benefits of two different doses of ticagrelor (60 mg or<a href="https://solaci.org/en/2018/03/21/new-study-shows-ticagrelor-aspirin-reduce-events-rate/" title="Read more" >...</a>

The 10 Commandments of ESC’s New STEMI Guidelines

The authors have given an entertaining account of the most relevant points and differences between the new STEMI guidelines and the prior ones, from 2014. The article features 10 points resembling the ten commandments, which makes it easy to read, compared to the tedious task of reading the complete guidelines. 1) The emergency systems should help<a href="https://solaci.org/en/2018/01/30/the-10-commandments-of-escs-new-stemi-guidelines/" title="Read more" >...</a>

Clopidogrel or Ticagrelor in Patients with Acute Coronary Syndrome Treated with New-Generation DES: CHANGE DAPT

Courtesy of Dr. Pablo Baglioni. This is a prospective observational study with a 1-year follow-up analyzing 2062 patients with acute coronary syndrome (ACS) who have been treated with coronary angioplasty using new-generation drug-eluting stents (DES). Patients were included between December 21, 2012 and August 25, 2015. On May, 2014, due to changes in international guidelines, clopidogrel<a href="https://solaci.org/en/2017/12/15/clopidogrel-or-ticagrelor-in-patients-with-acute-coronary-syndrome-treated-with-new-generation-des-change-dapt/" title="Read more" >...</a>

Angioplastias complejas: ¿Factor determinante para definir el tiempo de antiagregación?

Complex PCI: DAPT defining factor?

Courtesy of Dr. Alejandro Lakowsky, MTSAC. The Journal of the American College of Cardiology (JACC) has recently published a study on the role of coronary anatomy and PCI technical difficulty in the cost benefit ratio of prolonged vs. short post procedural  DAPT. This study was carried out by Robert Yeh, Laura Mauri and the DAPT trial<a href="https://solaci.org/en/2017/12/12/complex-pci-dapt-defining-factor/" title="Read more" >...</a>